MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects of panobinostat nanoparticle formulation
MTX110 (MTX110) in treating participants with newly-diagnosed diffuse intrinsic pontine
glioma. Panobinostat nanoparticle formulation MTX110 may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sabine Mueller, MD, PhD
Collaborators:
Midatech Pharma US Inc. Pacific Pediatric Neuro-Oncology Consortium